share_log

美股异动 | 礼来(LLY.US)终止PD-1激动剂候选药物研究 AnaptysBio(ANAB.US)暴跌超20%

US stocks anomaly | eli lilly and co (LLY.US) terminates research on PD-1 agonist candidate drug, AnaptysBio (ANAB.US) plunges over 20%.

Zhitong Finance ·  Oct 30 22:26

AnaptysBio is advancing a arthritis therapy similar to Eli Lilly and Co's PD-1 agonist antibody Peresolimab.

According to the Securities Times APP, on Wednesday, AnaptysBio (ANAB.US) stock price fell, dropping more than 20% to $24.455 as of the time of publication. AnaptysBio is advancing an arthritis therapy similar to Eli Lilly and Co (LLY.US)'s PD-1 agonist antibody Peresolimab. AnaptysBio's stock price plummeted after Eli Lilly announced the decision to terminate the research on this candidate drug.

In July of this year, H.C. Wainwright initiated coverage on AnaptysBio, with a 'buy' rating and a target price of $55. The firm believes that its PD-1 agonist rosnilimab may be more effective than peresolimab. Preliminary data from rosnilimab's trials is expected to be released in the first quarter of 2025.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment